Published in Int J Radiat Oncol Biol Phys on March 21, 2013
New challenges in high-energy particle radiobiology. Br J Radiol (2014) 1.08
Promise and pitfalls of heavy-particle therapy. J Clin Oncol (2014) 0.85
Benefits, risks, and safety of external beam radiation therapy for breast cancer. Int J Womens Health (2015) 0.81
Cardiac avoidance in breast radiotherapy: many choices for a worthwhile objective. Front Oncol (2014) 0.81
Early toxicity in patients treated with postoperative proton therapy for locally advanced breast cancer. Int J Radiat Oncol Biol Phys (2015) 0.78
New strategies in radiation therapy: exploiting the full potential of protons. Clin Cancer Res (2013) 0.78
Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. In regard to MacDonald et al. Int J Radiat Oncol Biol Phys (2014) 0.75
Axillary irradiation omitting axillary dissection in breast cancer: is there a role for shoulder-sparing proton therapy? Br J Radiol (2015) 0.75
Proton therapy - Present and future. Adv Drug Deliv Rev (2016) 0.75
A Literature Survey on Cost-Effectiveness of Proton Beam Therapy in the Management of Breast Cancer Patients. Iran J Cancer Prev (2015) 0.75
Joint Estimation of Cardiac Toxicity and Recurrence Risks After Comprehensive Nodal Photon Versus Proton Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys (2016) 0.75
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 10.87
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell (2004) 8.06
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 7.35
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 6.69
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol (2013) 6.56
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol (2008) 5.28
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med (2004) 4.84
A failure analysis of invasive breast cancer: most deaths from disease occur in women not regularly screened. Cancer (2013) 4.21
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst (2005) 4.19
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res (2006) 4.11
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res (2009) 3.65
Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant (2007) 3.58
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol (2007) 3.50
Prospective study of wide excision alone for ductal carcinoma in situ of the breast. J Clin Oncol (2006) 3.33
The cost-effectiveness of alendronate in the management of osteoporosis. Bone (2007) 2.75
Cohort profile: updating the cohort profile for the MRC National Survey of Health and Development: a new clinic-based data collection for ageing research. Int J Epidemiol (2011) 2.75
Nomogram for the prediction of having four or more involved nodes for sentinel lymph node-positive breast cancer. J Clin Oncol (2008) 2.72
Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A (2012) 2.66
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.65
Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys (2007) 2.55
Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med (2009) 2.39
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res (2009) 2.35
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun (2004) 2.29
Low magnitude mechanical loading is osteogenic in children with disabling conditions. J Bone Miner Res (2004) 2.15
Is excisional biopsy required after a breast core biopsy yields lobular neoplasia? AJR Am J Roentgenol (2012) 2.11
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer (2013) 2.10
Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. Clin Cancer Res (2013) 2.09
Accelerated partial breast irradiation with low-dose-rate interstitial implant brachytherapy after wide local excision: 12-year outcomes from a prospective trial. Int J Radiat Oncol Biol Phys (2011) 2.06
Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med (2009) 2.04
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res (2008) 2.00
Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapy. J Clin Oncol (2011) 1.99
Occult nipple involvement in breast cancer: clinicopathologic findings in 316 consecutive mastectomy specimens. J Clin Oncol (2009) 1.99
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol (2003) 1.96
New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol (2010) 1.95
Nipple Loss following Nipple-Sparing Mastectomy. Plast Reconstr Surg (2016) 1.95
Offering participants results of a clinical trial: sharing results of a negative study. Lancet (2005) 1.90
Proton beams to replace photon beams in radical dose treatments. Acta Oncol (2003) 1.87
EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol (2010) 1.86
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res (2010) 1.83
Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.79
Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med (2009) 1.79
Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys (2010) 1.76
Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med (2011) 1.75
Temporal lobe epilepsy and GEFS+ phenotypes associated with SCN1B mutations. Brain (2006) 1.72
Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy. J Clin Oncol (2012) 1.70
Functional proteomics approach to investigate the biological activities of cDNAs implicated in breast cancer. J Proteome Res (2006) 1.66
Mammographic screening: patterns of use and estimated impact on breast carcinoma survival. Cancer (2004) 1.66
Breast cancer version 3.2014. J Natl Compr Canc Netw (2014) 1.63
Validation of a web-based predictive nomogram for ipsilateral breast tumor recurrence after breast conserving therapy. J Clin Oncol (2010) 1.59
Temporo-spatial IMRT optimization: concepts, implementation and initial results. Phys Med Biol (2005) 1.59
Breast Cancer Version 2.2015. J Natl Compr Canc Netw (2015) 1.59
A case study in proton pencil-beam scanning delivery. Int J Radiat Oncol Biol Phys (2010) 1.57
Risk of lymphedema after regional nodal irradiation with breast conservation therapy. Int J Radiat Oncol Biol Phys (2003) 1.57
Chest wall radiotherapy: middle ground for treatment of patients with one to three positive lymph nodes after mastectomy. Int J Radiat Oncol Biol Phys (2009) 1.55
The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol (2012) 1.53
Sox2 protein expression is an independent poor prognostic indicator in stage I lung adenocarcinoma. Am J Surg Pathol (2010) 1.53
Beyond biologics: absorbable mesh as a low-cost, low-complication sling for implant-based breast reconstruction. Plast Reconstr Surg (2014) 1.53
Prospective trial of real-time electronic surveillance to expedite early care of severe sepsis. Ann Emerg Med (2011) 1.51
Desmoid tumor: analysis of prognostic factors and outcomes in a surgical series. Ann Surg Oncol (2012) 1.51
Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys (2006) 1.50
Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol (2014) 1.46
Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res (2012) 1.45
Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. J Neurosurg (2012) 1.45
Case records of the Massachusetts General Hospital. Case 32-2007. A 62-year-old woman with a second breast cancer. N Engl J Med (2007) 1.43
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer (2004) 1.42
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol (2010) 1.42
Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol (2008) 1.42
Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas. Mod Pathol (2012) 1.41
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.40
Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res (2003) 1.39
Breast reconstruction following nipple-sparing mastectomy: predictors of complications, reconstruction outcomes, and 5-year trends. Plast Reconstr Surg (2014) 1.39
Prognostic significance of grading in lung adenocarcinoma. Cancer (2010) 1.39
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2014) 1.38
Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. Mol Cancer Res (2009) 1.37
Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res (2013) 1.36
A dosimetric comparison of proton and intensity-modulated photon radiotherapy for pediatric parameningeal rhabdomyosarcomas. Int J Radiat Oncol Biol Phys (2008) 1.34
Optimization of current modulation function for proton spread-out Bragg peak fields. Med Phys (2006) 1.33
Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg (2006) 1.32
Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer (2009) 1.32
Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys (2008) 1.32
Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol (2010) 1.30
The feasibility of using natural language processing to extract clinical information from breast pathology reports. J Pathol Inform (2012) 1.30
Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. Int J Radiat Oncol Biol Phys (2005) 1.28
Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. Int J Radiat Oncol Biol Phys (2008) 1.27